JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.


Dysregulation of Janus kinase (JAK)-signal transducer and activator of transcription signaling is central to the pathogenesis of myelofibrosis (MF). JAK2 inhibitor therapy in MF patients results in a rapid reduction of the degree of splenomegaly, yet the mechanism underlying this effect remains unknown. The in vitro treatment of splenic and peripheral blood… (More)
DOI: 10.1182/blood-2014-02-558015


8 Figures and Tables